WASHINGTON — Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.
The states' attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained sales representatives to encourage doctors to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.
05:35 Arkansas carries out first execution since 2005 after Supreme Court denies stay requests19
05:18 The Latest: Inmate lost consciousness quickly, witnesses say24
05:18 Arkansas Puts Ledell Lee to Death, in Its First Execution Since 200525
01:38 Arkansas courts stay execution, block state from using lethal injection drug35